<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083222</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 757456-CS3</org_study_id>
    <nct_id>NCT04083222</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously for 8 Weeks to Hypertensive Subjects With Uncontrolled Blood Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of IONIS-AGT-LRx on plasma angiotensinogen (AGT) and
      systolic blood pressure (SBP) in uncontrolled hypertensive participants who are on two to
      three antihypertensive medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a Phase 2, double-blind, randomized, placebo-controlled study in up to 30
      participants. Participants will be randomized in a 2:1 ratio and will receive a once-weekly
      subcutaneous (SC) treatment with either IONIS-AGT-LRx or placebo, with an additional loading
      dose administered on Study Day 3. The treatment will last for 8 weeks and the post-treatment
      period will last for 13 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Plasma Angiotensinogen (AGT) from Baseline to Study Day 57 (Study Week 9) Compared to Placebo</measure>
    <time_frame>Baseline to Week 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure (SBP) from Baseline to Each Scheduled, Post-Baseline Visit</measure>
    <time_frame>Baseline up to Day 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Plasma AGT from Baseline to Each Scheduled, Post-Baseline Visit</measure>
    <time_frame>Baseline up to Day 141</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>IONIS-AGT-LRx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IONIS-AGT-LRx administered subcutaneously once-weekly for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matching solution administered subcutaneously once-weekly for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IONIS-AGT-LRx</intervention_name>
    <description>IONIS-AGT-LRx administered subcutaneously</description>
    <arm_group_label>IONIS-AGT-LRx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching IONIS-AGT-LRx solution administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Males or females aged 18-75 inclusive and weighing ≥ 50 kilograms (kg) at the time of
             informed consent

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or
             post-menopausal

          -  Males must be surgically sterile or, abstinent or, if engaged in sexual relations with
             a woman of child-bearing potential (WOCBP), the participant or participant's
             non-pregnant female partner must be using a highly effective contraceptive method

          -  Body mass index (BMI) ≤ 35.0 kg/square meter (m^2)

          -  Participant must have been diagnosed with essential hypertension for a minimum of 3
             months prior to screening

          -  At screening, the participant must have been on a stable regimen of 2 to 3
             antihypertensive medications for at least 1 month prior to screening and will be
             required to maintain this regimen throughout the study, using either an
             angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker
             (ARB), as well as 1 or 2 additional antihypertensive medications in the following
             categories: beta blocker, acebutolol, atenolol, betaxolol, bisoprolol, carvedilol,
             labetalol, metoprolol, nadolol, nebivolol, propranolol, pindolol, calcium channel
             blocker or, non-potassium sparing diuretic

        Exclusion Criteria:

          -  Clinically significant abnormalities in medical history, screening laboratory results,
             or physical examination that would render the participant unsuitable for inclusion

          -  History of secondary HTN

          -  The use of the following at time of screening and during the course of the study:

               -  Other medications for the treatment of HTN (e.g., clonidine, guanfacine,
                  guanabenz, alpha-methyldopa, hydralazine, minoxidil, diazoxide, renin inhibitors)

               -  Medications that may cause hyperkalemia (e.g., cyclosporine or tacrolimus,
                  pentamidine, trimethoprim-sulfamethoxazole, all heparins)

               -  Oral or SC anticoagulants (e.g., warfarin, rivaroxaban, apixaban, heparin,
                  lovenox)

               -  Organic nitrate preparations (e.g., nitroglycerin, isosorbide mononitrate,
                  isosorbide dinitrate, or pentaerythritol)

               -  Phosphodiesterase 5 inhibitors (e.g., sildenafil, tadalafil, vardenafil,
                  avanafil)

               -  Potassium-sparing diuretics (e.g., eplerenone, spironolactone, amiloride,
                  triamterene)

          -  Unstable/underlying cardiovascular disease defined as:

               -  Any history of congestive heart failure (New York Heart Association [NYHA] class
                  II-IV)

               -  Any history of previous stroke, transient ischemic attack, unstable or stable
                  angina pectoris, or myocardial infarction prior to screening

               -  12-lead electrocardiogram (ECG) corrected using Fridericia's formula (QTcF) &gt; 450
                  milliseconds (msec) in males and &gt; 470 msec in females at screening, or a history
                  or evidence of long QT syndrome

               -  Any clinically significant active atrial or ventricular arrhythmias

               -  Any history of coronary bypass or percutaneous coronary intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Central Alabama Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Excel Medical Clinical Trials</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Institute for Clinical Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Clinical Research - Lyndhurst</name>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Clinical Research LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Hypertensive</keyword>
  <keyword>AGT</keyword>
  <keyword>Angiotensinogen</keyword>
  <keyword>Blood Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

